BACKGROUND:: The pathology of chronic obstructive pulmonary disease (COPD) includes
both obstructive and inflammatory components. OBJECTIVE:: The aim of this study was to …

Background: Combined treatment with inhaled corticosteroids and long acting β2 agonists is
approved for the treatment of chronic obstructive pulmonary disease (COPD), but little is …

Background: This is the first comparison of two combination therapies, fluticasone
propionate/salmeterol and ipratropium bromide/albuterol (salbutamol), for the treatment of …

Bronchodilator agents are central to the symptomatic management of Chronic Obstructive
Pulmonary Disease (COPD), and long-acting inhaled bronchodilators are regarded as more …

Background: Inhaled corticosteroids (ICSs) and long-acting β2-agonists (LABAs) are used to
treat moderate to severe chronic obstructive pulmonary disease (COPD). Objective: To …

This retrospective analysis of data from two multi-center, randomized, double-blind, parallel
group studies compared the efficacy of fluticasone propionate/salmeterol (FSC) 250/50mcg …

Chronic-obstructive pulmonary disease (COPD) is a global public health problem and its
impact is increasing. Although only smoking cessation has been shown to alter the natural …

BACKGROUND: The predictive factors for treatment response in patients with severe
chronic obstructive pulmonary disease (COPD) are unknown. We investigated predictive …

Prevention and treatment of COPD exacerbations are recognized as key goals in disease
management. This randomized, double-blind, parallel-group, multicenter study evaluated …

Inhaled corticosteroids are often used in the treatment of stable chronic obstructive
pulmonary disease (COPD), however, studies of these agents have had mixed results …